Victoria Chell

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

Victoria Chell, Kathryn Balmanno, Annette S. Little et al. · Oncogene · 2012 · 141 citations

Medicine, Cancer Biology, Oncology +14

Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1)

D.S. Williamson, Garrick P. Smith, P. Acheson-Dossang et al. · Journal of Medicinal Chemistry · 2017 · 47 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase

Paul A. Brough, Lisa Baker, Simon T. Bedford et al. · Journal of Medicinal Chemistry · 2017 · 38 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +13

Design and Synthesis of Pyrrolo[2,3-<i>d</i>]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate

D.S. Williamson, Garrick P. Smith, Gitte Kobberøe Mikkelsen et al. · Journal of Medicinal Chemistry · 2021 · 38 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors

Garrick P. Smith, Lassina Badolo, Victoria Chell et al. · Bioorganic & Medicinal Chemistry Letters · 2017 · 16 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13